It has also been observed that, among YAP-positive malignancies, targeting α2β1 integrin and NUAK family kinase 2 (NUAK2) expression blocks tumor progression by inhibiting the MST-YAP cascade and actin-myosin activity (21–23). The gene discussed is YAP1; the disease is neoplasm.